Loading...
Arix Bioscience plc
ARIX.L•LSE
Healthcare
Biotechnology
£142.00
£-1.50(-1.05%)

Over the last four quarters, Arix Bioscience plc's revenue moved from -$812000.00 in Q3 2022 to $21.14M in Q2 2023. Operating income in Q2 2023 was $18.16M, with a strong operating margin of 86%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Arix Bioscience plc remained robust at $18.22M, reflecting operational efficiency. Net income rose to $12.48M, with an EPS of $0.09. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan